My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Cybin Inc. Common Shares (NY:CYBN)

8.280 UNCHANGED

Last Price Updated: 8:00 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Cybin Inc. Common Shares

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Psychedelic Stock Gainers And Losers From January 18, 2022 ↗

January 18, 2022

GAINERS: Cybin (AMEX:

Via Benzinga

Psyched: Delix Raises $30M, New Ketamine Study For Alcohol Use Disorder, FDA Approves Ketamine Trial For ALS ↗

January 18, 2022

New Awakn Study Shows Ketamine Has Potential To Treat Alcoholism Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB:

Via Benzinga

Cybin Notes 'Milestone' Step with USPTO Notice of Allowance for CYB004 ↗

January 12, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advi...

Via Benzinga

Psychedelics Biotech Companies Mark New Milestones In Drug Development Pipelines: Field Trip, Cybin and Wesana ↗

January 11, 2022

On Tuesday, three public companies in the psychedelics/biotech space announced significant milestones in their drug development pipelines.

Via Benzinga

Cybin CEO Participation in Upcoming Events Recognizes Company Expertise ↗

January 11, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advi...

Via Benzinga

Cybin Releases Q2 Financial Results ↗

November 15, 2021

Cybin (NYSE:

Via Benzinga

Why Cybin Shares Are Rising ↗

January 11, 2022

Cybin Inc (NASDAQ: CYBN) shares are trading higher after the company announced an Institutional Review Board granted approval for a Cybin-sponsored feasibility study using Kernel...

Via Benzinga

Cybin Highlights Adelia's Milestone Achievement ↗

January 10, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Cybin (NYSE: CYBN), a biotechnology...

Via Benzinga

Pure-Play Marijuana- & Psychedelic Compounds-Based Drug Stocks Index Is Down By 66% From 2021 High ↗

January 09, 2022

There are 16 remaining constituents of our Marijuana & Psychedelic Compounds-Based Drug Stocks Index is now DOWN -65.9% from its highs in 2021. Here are the details for each of its constituents.

Via Talk Markets

Cybin Witnessing Advancement in R&D Pipeline ↗

December 29, 2021

Cybin (NYSE: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently released its financial and operating...

Via Benzinga

Steep Decline In Cannabis & Psychedelic Compounds-Based Drug Stocks Continues: DOWN -16.6% MTD ↗

December 24, 2021

All 12 constituents in the Marijuana & Psychedelic Compounds-Based Drug Stocks Index continue to decline. How do their performances compare month-to-date and YTD?

Via Talk Markets

Marijuana & Psychedelic Compounds-Based Drug Stocks Now Down -16% YTD ↗

December 17, 2021

A look at which index has done the best so far in December: the Marijuana Drug Stocks Index or the Psychedelic Compounds-Based Drug Stocks Index.

Via Talk Markets

Cybin Receives Notice of Allowance from U.S. Patent Office ↗

December 15, 2021

Cybin (NYSE: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has been awarded a Notice of Allowance from the U.S. Patent and Trademark Office (...

Via Benzinga

Cybin Developing Safer, More Effective Psilocybin Therapies ↗

December 14, 2021

Cybin (NYSE: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently announced positive results from a...

Via Benzinga

Cybin to Fund, Support Psychedelic Clinic at Manhattan Hospital ↗

December 10, 2021

Company receives grant to fund clinic for marginalized, underserved NYC communities New clini...

Via Benzinga

Psilera's DMT-Derived Drug Sees Positive Results in Pre-Clinical Study ↗

December 09, 2021

Psilera is a Florida-based biotechnology company focused on developing drugs to treat mental disorders using non-hallucinogenic derivatives from psychedelic compounds. The...

Via Benzinga

Topics Derivatives

Cybin Touts Highlights of 'Transformative' Second-Quarter Performance ↗

December 02, 2021

The report notes significant and swift advancements in the company R&D pipeline and overall business Preliminary data indicates CYB003 may provide significant treatment...

Via Benzinga

Cybin Announces FDA Approvals, Participation in Conference ↗

December 01, 2021

Cybin (NYSE:

Via Benzinga

Psilocybin Trials For COVID-Related Distress Of Healthcare Professionals Could Validate New Psychotherapy Model ↗

November 30, 2021

Cybin (NYSE:CYBN), a biotech company focused on progressing ...

Via Benzinga

Cybin To Test Psychedelic-Assisted Psychotherapy For COVID-Related Distress ↗

November 30, 2021

The FDA authorized an investigator-initiated Phase 2 trial evaluating Cybin Inc's (NYSE: CYBN) psychedelic-assisted psychotherapy with psilocybin for...

Via Benzinga

Cybin Supports Psychedelic Treatment Clinic Through Grant ↗

November 23, 2021

Cybin (NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced it has awarded a grant for the first...

Via Benzinga

NY's Lenox Hill Hospital With Cybin-Awarded Grant Will Provide Psychedelic Therapy To City's Underserved ↗

November 23, 2021

Psychedelic therapy company, Cybin Inc. (NEO: CYBN) (NYSE:

Via Benzinga

Psychedelic Drug Stocks Continued To Decline Last Week ↗

November 21, 2021

The 12 constituents in our Pure-Play Psychedelic Compounds-Based Drug Stocks Index declined -5.7% last week; it's now -16.1% so far in November.

Via Talk Markets

Cybin 'One Step Closer' to Creating Best Therapy for Mental Health ↗

November 19, 2021

Company releases positive results from a pre-clinical study focusing on psilocybin program CYB003 Multiple academic studies have shown that psilocybin may have the potential to...

Via Benzinga

Cybin Reports Q2 Financial Results And Latest News, Including FDA & DEA Research Approvals ↗

November 15, 2021

Toronto-based, Cybin Inc. (NEO: CYBN) (NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics,” reported its unaudited...

Via Benzinga

Psychedelic Drug Stocks Have Plunged -10.6%, On Average, So Far In November ↗

November 14, 2021

Our Pure-Play Psychedelic Compounds-Based Drug Stocks Index has declined -10.6% in the last 2 weeks; it's still up +7.8% since the end of September.

Via Talk Markets

Can The Psychedelics Boom Go Bust? A Conversation With Cybin Chief Clinical Officer Dr. Alex Belser ↗

November 14, 2021

This article was originally published on Psychedelic Spotlight and appears here with permission. "Something that people used t...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021 ↗

November 19, 2021

Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE:

Via Benzinga

Compass Pathways Phase II Results: A Disappointment For Some, An Opportunity For Others ↗

November 11, 2021

Compass Pathways reported

Via Talk Markets

Cybin Unveils Data Suggesting Its Novel Psilocybin Analog Is the 'Superior Molecule' ↗

November 11, 2021

This article was originally published on

Via Benzinga

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.